Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 4. Pathological Diagnosis and Staging after Thyroidectomy 2024
10.11106/ijt.2024.17.1.61
- Author:
Su-Jin SHIN
1
;
Hee Young NA
;
Ho-Cheol KANG
;
Sun Wook KIM
;
Dong Gyu NA
;
Young Joo PARK
;
Young Shin SONG
;
Eun Kyung LEE
;
Dong-Jun LIM
;
Yun Jae CHUNG
;
Chan Kwon JUNG
;
Author Information
1. Department of Pathology, Gangnam Severance Hospital, Seoul, Korea
- Publication Type:REVIEW ARTICLES
- From:International Journal of Thyroidology
2024;17(1):61-67
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Postoperative pathological diagnosis of differentiated thyroid cancer (DTC) is important to confirm the diagnosis and predict the risk of recurrence and death. Further treatment plans, such as completion thyroidectomy, radioiodine remnant ablation, or external beam radiation therapy, are then opted for to reduce the predicted risk of recurrence or death. The World Health Organization has classified thyroid cancers into seven distinct categories based on the molecular profile and tumor cell origin. Our recommendation is applicable to differentiated follicular cell-derived carcinoma, the most common form of thyroid cancer, and cribriform morular thyroid carcinoma. Postoperative clinical and pathological staging is recommended for all patients with DTC to determine their prognosis and subsequent treatment decisions. In particular, the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system is recommended for staging DTCs for disease mortality prediction and national cancer registries. The information in the pathology report, including histologic features of the tumor that are necessary for AJCC/UICC staging and recurrence prediction, can help assess the patient’s risk.
